Key result
Liposomal doxorubicin and PDE5 inhibitors show promise in minimizing cardiotoxicity while enhancing ovarian cancer treatment.
Why the study?
Chemotherapeutic agents for ovarian cancer, particularly anthracyclines such as doxorubicin, cause cardiotoxicity that can lead to heart failure and death, necessitating treatments that are effective against cancer and less harmful to the heart.
This review highlights the cardiotoxic risks of ovarian cancer treatments and summarizes emerging cardioprotective strategies, emphasizing the need for further research to balance oncologic efficacy with cardiovascular safety.
Hypothesis-generating for PDE5 inhibitors and liposomal doxorubicin in ovarian cancer; randomized trials needed before clinical adoption.
Ovarian Cancer (OC) is recognized as the most lethal gynecologic malignancy, characterized by numerous genetic mutations that trigger uncontrolled cellular growth and replication. Emerging evidence suggests that non-coding RNAs including miRNAs and lncRNAs significantly influence OC through their multiple roles including tumor initiation, progression, metastasis, immune evasion, and chemoresistance, making them promising diagnostic markers and therapeutic targets. The primary approach to treating OC typically involves cytoreductive surgery followed by chemotherapy. However, the chemotherapeutic agents, particularly the anthracyclines such as doxorubicin (DOX), are known for their cardiotoxic effects, which can range from acute to chronic, potentially leading to heart failure and death. To enhance the overall treatment response and to minimize cardiotoxicity, alternative strategies have been explored. These include the use of liposomal doxorubicin (DOXIL) as a substitute for DOX, various radiotherapies, immunotherapies, and the co-administration of angiotensin-converting enzyme inhibitors and/or beta-blockers. Phosphodiesterase-5 inhibitors (PDE5i) have also demonstrated efficacy in reducing cardiotoxicity linked to cancer treatments and in promoting apoptosis in cancer cells across multiple cancer types. Although there is no current clinical trial directly examining the impact of PDE5i on reducing cardiotoxicity in OC, however emerging therapies such as Withaferin A, PARP inhibitors, and nanoparticle combination therapy show promise. Additional research is essential to develop treatments that are both effective against OC and less harmful to the heart.
No takes yet. Share an insight, caveat, or question.
Nair et al. (2025) conducted a review in Ovarian Cancer and Chemotherapy-Induced Cardiotoxicity. Cardioprotective strategies (e.g., PDE5 inhibitors, liposomal doxorubicin) was evaluated. Emerging therapeutic strategies, including liposomal doxorubicin and PDE5 inhibitors, show promise in enhancing ovarian cancer treatment efficacy while minimizing chemotherapy-induced cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: